Table 4 The capacity to predict 2 and 6 months treatment outcomes by 11 biomarkers (BM) which changed consistently on ATT was analyzed applying logistic regression, leave-10-out cross-validation while adjusting for micronutrient supplementation.

BM entered in the model		Prediction by BM measured at baseline				Prediction by BM measured after 2 months		Prediction by the change in BM from baseline to 2 months
		Outcome at 2 months		Outcome at 6 months		Outcome at 6 months		Outcome at 6 months
		Int. est. ^a	Cross-validation	Int. est. ^a	Cross-validation	Int. est. ^a	Cross-validation	Int. est. ^a	Cross-validation
single biomarkers	BCL2	0,614	0,568	0,762	0,75	0,651	0,587	0,759	0,648
	BLR1	0,636	0,614	0,738	0,702	0,619	0,587	0,704	0,63
	CASP8	0,614	0,58	0,75	0,762	0,635	0,619	0,704	0,685
	CD3E	0,636	0,568	0,726	0,714	0,651	0,587	0,741	0,667
	CD4	0,602	0,545	0,714	0,679	0,603	0,556	0,685	0,63
	CD19	0,625	0,557	0,762	0,714	0,651	0,587	0,667	0,667
	FCGR1A	0,625	0,591	0,738	0,702	0,651	0,635	0,685	0,537
	FPR1	0,625	0,58	0,75	0,714	0,651	0,603	0,722	0,667
	IL7R	0,625	0,557	0,75	0,75	0,651	0,587	0,741	0,667
	TGFBR2	0,614	0,591	0,75	0,75	0,651	0,571	0,704	0,574
	MMP9	0,58	0,557	0,738	0,702	0,698	0,683	0,778	0,759
signatures	FCGR1A & BLR1	0,648	0,568	0,738	0,714	0,667	0,603	0,685	0,537
	11 markers ^*	0,727	0,523	0,762	0,679	0,73	0,619	0,759	0,593
	10 markers ^**	0,705	0,523	0,786	0,643	0,746	0,651	0,759	0,593

^a Internal estimate of accuracy. ^* Cross-validation of the combination of all 11 biomarkers that consistently changed with treatment (BCL2, BLR1, CASP8, CD19, CD3E, CD4, FCGR1A, FPR1, IL7R, MMP9, and TGFBR2). ^** Cross-validation of the combination of the same markers as above, but excluding CD4.
Biomarkers measured at the start of ATT (baseline), at 2 months, and the corresponding change in score were assessed. Prediction accuracy in the cross-validation estimates are bolded.

Search